World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
111
Citations
62551
World Ranking
830
National Ranking
28

Medicine

D-Index
118
Citations
71976
World Ranking
3980
National Ranking
110

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award
  • 2017 - Fellow of the Australian Academy of Health and Medical Science

Overview

Sherene Loi is affiliated with the Peter MacCallum Cancer Centre in Australia. Their research primarily focuses on oncology, with significant contributions to advanced breast cancer therapies, cancer immunotherapy and biomarkers, and HER2/EGFR in cancer research. The main fields of study for Sherene Loi encompass medicine and biochemistry, genetics, and molecular biology, with notable work in the subfields of oncology, pulmonary and respiratory medicine, cancer research, genetics, and immunology.

The scientist has collaborated frequently with several researchers, including Roberto Salgado, Seock-Ah Im, Peter Schmid, Hope S. Rugo, and Sibylle Loibl. Publications have appeared extensively in high-impact medical and scientific journals such as Cancer Research, Annals of Oncology, the Journal of Clinical Oncology, npj Breast Cancer, and Clinical Cancer Research.

Among the recent influential papers associated with Sherene Loi's research are:

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial, 2020, The Lancet
  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer, 2021, Annals of Oncology
  • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death, 2020, Journal for ImmunoTherapy of Cancer
  • Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer, 2022, New England Journal of Medicine
  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study, 2020, The Lancet Oncology

The key topics explored in their work include advanced breast cancer therapies, cancer immunotherapy and biomarkers, HER2/EGFR pathways in cancer, breast cancer treatment studies, cancer treatment and pharmacology, cancer genomics and diagnostics, and cancer cells and metastasis.

Sherene Loi was awarded Fellowship of the Australian Academy of Health and Medical Science in 2017.

Best Publications

  • The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

    R. Salgado;C. Denkert;S. Demaria;N. Sirtaine

  • Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

    Christos Sotiriou;Pratyaksha Wirapati;Sherene Loi;Adrian Harris

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi

  • Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

    Marc Buyse;Sherene Loi;Laura van't Veer;Giuseppe Viale

  • Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

    S. Loi;S. Loi;S. Michiels;S. Michiels;R. Salgado;N. Sirtaine

  • Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

    Sherene Loi;Nicolas Sirtaine;Fanny Piette;Roberto Salgado

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

    Javier Cortes;David W Cescon;Hope S Rugo;Zbigniew Nowecki

  • Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

    Carsten Denkert;Gunter von Minckwitz;Jan C. Brase;Bruno V. Sinn

  • CD4+ follicular helper T cell infiltration predicts breast cancer survival

    Chunyan Gu-Trantien;Sherene Loi;Soizic Garaud;Carole Equeter

  • Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series,

    Christine Desmedt;Fanny Piette;Sherene Loi;Yixin Wang

  • Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    Peter Schmid;Hope S Rugo;Sylvia Adams;Andreas Schneeweiss

  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

    Rashmi K Murthy;Sherene Loi;Alicia Okines;Elisavet Paplomata

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Lorenzo Galluzzi;Ilio Vitale;Sarah Warren;Sandy Adjemian

  • Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis

    Peter Savas;Balaji Virassamy;Chengzhong Ye;Agus Salim;Agus Salim

  • Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

    Sherene Loi;Benjamin Haibe-Kains;Christine Desmedt;Françoise Lallemand

  • Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

    Samra Turajlic;Samra Turajlic;Kevin Litchfield;Hang Xu;Rachel Rosenthal

  • Clinical relevance of host immunity in breast cancer: from TILs to the clinic

    Peter Savas;Roberto Salgado;Carsten Denkert;Christos Sotiriou

  • Consensus guidelines for the detection of immunogenic cell death

    Oliver Kepp;Laura Senovilla;Ilio Vitale;Erika Vacchelli

Frequent Co-Authors

Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles
Roberto Salgado
Roberto Salgado Peter MacCallum Cancer Centre
Stefan Michiels
Stefan Michiels University of Paris-Saclay
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Sibylle Loibl
Sibylle Loibl Goethe University Frankfurt
Benjamin Haibe-Kains
Benjamin Haibe-Kains Princess Margaret Cancer Centre
Martine Piccart
Martine Piccart Université Libre de Bruxelles
Carsten Denkert
Carsten Denkert Philipp University of Marburg
Sylvia Adams
Sylvia Adams New York University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring medical careers beyond traditional MD programs, there are several alternative pathways that offer flexibility and accessibility. For those with a non-nursing background who wish to quickly enter the healthcare workforce, direct entry msn programs for non-nurses online provide streamlined routes to advanced nursing credentials.

Admission challenges can be a concern, but aspiring nurses have options. Some nursing programs with high acceptance rates allow students to start their education without highly competitive entry requirements, making the journey smoother for many applicants.

Not all healthcare careers require hands-on patient care. Growing demand for administrative professionals has increased the popularity of online medical billing and coding schools that accept fafsa, which provide flexible and affordable options for those interested in medical office roles.

Additionally, if standardized testing is a barrier, you can find nursing programs without teas that remove common entrance exam requirements, helping more students start their careers in healthcare. These diverse online programs can open doors to a range of rewarding medical professions.

Best Scientists Citing Sherene Loi

Trending Scientists